POSSIBILITIES FOR IMPROVEMENT OF THE EFFECTIVENESS OF SURGICAL TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER


如何引用文章

全文:

详细

Every year, the world is registering more than 225 thousand new cases of ovarian cancer, more than 140 thousand women die from this disease. The surgical treatment is key in the treatment of all stages of ovarian cancer. In some cases, when the tumor is a conglomerate and all anatomical landmarks are violated, removing this conglomerate without damaging the neighboring structures is a difficult task. That is why oncogynecological studies that have to respond to all occasions. In the article, the authors analyzed modern approaches to surgery, common ovarian cancer, and also discussed ways to improve the results of surgical treatment of this group of patients.

作者简介

S. Nikogosyan

N.N. Blokhin National Medical Research Center of Oncology

Email: seda.nikogosyan@bk.ru
доктор медицинских наук, ведущий научный сотрудник отделения комбинированных и лучевых методов лечения онкогинекологических заболеваний «НМИЦ онкологии им. Н.Н. Блохина» МЗ РФ Moscow, 115478, Russian Federation

M. Sekerskaya

N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russian Federation

V. Kuznetsov

N.N. Blokhin National Medical Research Center of Oncology

Moscow, 115478, Russian Federation

参考

  1. Bray F., Ferlay J., Laversanne M., Brewster D.H., Gombe Mbalawa C., Kohler B. et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int. J. Cancer. 2015; 137 (9): 2060-71. doi: 10.1002/ijc.29670.
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году. М.: МНИОИ им. П.А. Герцена; 2017.
  3. Аксель Е.М. Заболеваемость и смертность от злокачественных новообразований органов женской репродуктивной системы в России. Онкогинекология. 2015; (1): 6-15.
  4. Lowe K.A., Chia V.M., Taylor A., O’Malley C. et al. An international assessment of ovarian cancer incidence and mortality. Gynecol. Oncol. 2013; 130: 107-14.
  5. Morgan R.J., Armstrong D.K., Alvarez R.D. et al. Ovarian Cancer. NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 2016; 14: 1134-63.
  6. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics 2012. C.A. Cancer J. Clin. 2015; 65: 87-108.
  7. Badgwell D., Bast R.C., Jr. Early detection of ovarian cancer. Dis. Markers. 2007; 23: 397-410.
  8. Никогосян С.О., Кузнецов В.В. Рак яичников: вопросы диагностики и современные методы лечения. Врач. 2010: 9-16.
  9. Новикова Е.Г., Антошечкина Е.Т. Ошибки в диагностике и лечении злокачественных опухолей женских половых органов. В кн.: Чиссов В.И., Трахтенберг А.Х., ред. Ошибки в клинической онкологии. М.: Медицина; 2001: 422-55.
  10. Siegel R.L., Miller K.D., Jemal A. Cancer statistics 2016. C.A. Cancer J. Clin. 2016; 66: 7-30.
  11. Бохман Л.В. Руководство по онкогинекологии Л.: Медицина 1989. 464 с.
  12. Винокуров В JI. Рак яичников. Закономерности метастазирования и выбор адекватного лечения больных. Санкт-Петербург: Фолиант; 2004. 333 с.
  13. Никогосян С.О., Жорданиа К.И., Кедрова А.Г., Панченко И.В. Рак яичников: лекции по онкогинекологии. Под ред. М.И. Давыдова, В.В. Кузнецова М., 2009. С. 260-88.
  14. Козаченко В.П., ред. Клиническая онкология: Руководство для врачей. М.: Медицина; 2005.
  15. Griffith C.T. Surgical resections of tumour bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monograph. 1975; 42: 101-4.
  16. Meigs J.V. Tumors of the Female Pelvic Organs. Macmillan surgical monographs. 1934: 262-3.
  17. Khalil el-S.A. et al. Cytoreductive surgery for advanced epithelial tumors of the ovary: technical considerations and outcome. Natl. Canc. Inst. 2005; 17 (3): 158-64.
  18. Tentes A.A. et al. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int. J. Gynecol. Cancer. - 2006; 16 (2): 490-5.
  19. Onda T. et al. Ovarian cancer. Optimal cytoreduction for advanced epithelial ovarian cancer: a commentary. Gan To Kagaku Ryoho. 2007; 34 (11): 1735-9.
  20. Tropé C., Kaern J. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC). Eur. J. Surg. Oncol. 2006; 32 (8): 844-52.
  21. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A. Announcements. FIGO stages-1988 revision. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Groupstudy. Gynecol. Oncol. 1992; 47: 159-66.
  22. Marsden D.E., Friedlander M., Hacker N.F. Current management of epithelial ovarian carcinoma: a review. Semin Surg. Oncol. 2000; 19: 11-9.
  23. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a metaanalysis. J. Clin. Oncol. 2002; 20: 124859.
  24. Whitney C.W., Spirtos N. Gynecologic Oncology Group Surgical Procedures Manual. 2010 January: [Электронный документ] (https://gogmember.org/manuals/pdf/surgman.pdf).
  25. Sznurkowski J. J. En bloc pelvic resection for advanced ovarian cancer preceded by central ligation of vessels supplying the tumor bed: a description of surgical technique and a feasibility study. World J. Surg. Oncol. 2016 Apr 29;14:133. doi: 10.1186/s12957-016-0894-5.
  26. Chi D.S. et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 2006; 103 (2): 559-64.
  27. Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).Gynecol. Oncol. 2007; 106: 69-74.
  28. Winter W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S., Rose P.G. et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2008; 26: 83-9.
  29. du Bois A., Reuss A., Pujade-Lauraine E., et al. Role of Surgical Outcome as Prognostic Factor in Advanced Epithelial Ovarian Cancer: A Combined Exploratory Analysis of 3 Prospectively Randomized Phase 3 Multicenter Trials. Cancer. 2009; 115 (6): 1234-44.
  30. Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010; 363: 943-53.
  31. Rauh-Hain J.A., Rodriguez N., Growdon W.B., Goodman A.K., et al. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann. Surg. Oncol. 2012; 19 (3): 959-65. doi: 10.1245/ s10434-011-2100-x
  32. Румянцев А.А., Покатаев И.А., Тюляндина А.С., Тюляндин С.А. Вопросы качества хирургического лечения при раке яичников. https://doi.org/10.18027/2224-5057-2018-8-1-31-37
  33. Kehoe S., Hook J., Nankivell M. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. Chicago: 2013. ASCO Annual Meeting.
  34. Di Giorgio A. et al. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J. Surg. Oncol. 2013; 11: 64-72. doi: 10.1186/1477-7819-11-64.
  35. Houvenaeghel G., Gutowski M., Buttarelli M., Cuisenier J., et al. Modified Posterior Pelvic Exenteration for Ovarian Cancer. Int. J. Gynecol. Cancer. 2009; 19(5): 968-73. doi: 10.1111/IGC.0b013e3181a7f38b.
  36. Harter P., Muallem Z.M., Buhrmann C., Lorenz D., et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol. Oncol. 2011; 121: 615-9.
  37. Tanner et al. Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 2013; 128 (1): 28-33.
  38. Peiretti M., Zanagnolo V., Aletti G.D., Bocciolone L., Colombo N., Landoni F. et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubalcancer: Surgical and oncological outcomes. Single institution experience. Gynecol. Oncol. 2010; 119 (2): 259-64.
  39. Luyckx M., Leblanc E., Filleron T. et al. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. Int. J. Gynecol. Cancer. 2012; 22 (8): 1337-43. PMID: 22964527.
  40. Bristow R.E., et al. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. Journal of the American College of Surgeons. 2003; 1974: 565-74.

版权所有 © Eco-Vector, 2018


 


##common.cookie##